Urinary Peptidomic Signatures Predict Overall and Progression‐Free Survival in Bladder Cancer
PROTEOMICS · 2026-07 · 26 (7) · 169-180
DOI: 10.1002/pmic.70135 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS, online erschienen am 27.04.2026. Verfasst von Melika Ahangar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Biomarkers, Tumor, Peptides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Federal Ministry for Economic Affairs and Climate Protection, European Union's Horizon Europe MULTIR, Ministry of Science, Research and Technology of Iran.
Abstract (Originalsprache)
Clinicopathologic calculators for bladder cancer (BC) provide only moderate prognostic accuracy and do not capture the underlying molecular phenotypes. Herein, we applied capillary electrophoresis–mass spectrometry (CE–MS) to identify prognostic signatures in urine linked to BC outcome. In a discovery cohort ( n = 131; mean follow‐up 623 days), 114 survival‐associated peptides were significant prognostic factors for overall survival (OS) and were integrated into, and optimized as a 110‐peptide support vector machine (SVM) classifier (BC110). Validation of the BC110 classifier was performed in an independent cohort ( n = 102; mean follow‐up 1605 days), resulting in an AUC of 0.78 ( p = 0.03). Functional enrichment analysis revealed that the BC110 peptide panel predominantly reflects extracellular matrix (ECM) remodeling and collagen‐related pathways, alongside additional biological processes including coagulation, complement activation, oxidative stress, and RNA processing, consistent with active tumor–stroma crosstalk. This urine‐based classifier enables non‐invasive risk stratification and may complement guideline calculators by identifying high‐risk patients for adjuvant therapy and low‐risk groups for reduced surveillance, potentially lowering reliance on repeated cystoscopy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
- Department of Biomarker Research, Mosaiques Diagnostics GmbH, Hannover, Germany.
- First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Institute For Molecular Cardiovascular Research, RWTH Aachen University Hospital, Aachen, Germany.
- Centre of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Förderung
- Federal Ministry for Economic Affairs and Climate Protection
- European Union's Horizon Europe MULTIR
- Ministry of Science, Research and Technology of Iran
- Iran National Science Foundation
- Ministry of Science Research and Technology
Zitieren
APA
Ahangar, M., Mischak, H., Moulavasilis, N., Stravodimos, K., Mahjoubi, F., Jankowski, J., Frantzi, M., & Vlahou, A. (2026). Urinary Peptidomic Signatures Predict Overall and Progression‐Free Survival in Bladder Cancer. PROTEOMICS, 26(7), 169-180. https://doi.org/10.1002/pmic.70135
Vancouver
Ahangar M, Mischak H, Moulavasilis N, Stravodimos K, Mahjoubi F, Jankowski J, et al. Urinary Peptidomic Signatures Predict Overall and Progression‐Free Survival in Bladder Cancer. PROTEOMICS. 2026;26(7):169-180. doi:10.1002/pmic.70135
BibTeX
@article{Ahangar2026,
author = {Ahangar, Melika and Mischak, Harald and Moulavasilis, Napoleon and Stravodimos, Konstantinos and Mahjoubi, Frouzandeh and Jankowski, Joachim and Frantzi, Maria and Vlahou, Antonia},
title = {Urinary Peptidomic Signatures Predict Overall and Progression‐Free Survival in Bladder Cancer},
journal = {PROTEOMICS},
year = {2026},
volume = {26},
number = {7},
pages = {169--180},
doi = {10.1002/pmic.70135}
}
EUVIMED